Table 3.
Changes in clinical and inflammatory markers and AT genes, 12 months following bariatric surgery in validation cohort 2. Values are mean ± SD. CLS—crown-like structures, VAT—visceral adipose tissue, SAT—subcutaneous adipose tissue. ns—not significant (p > 0.05).
| Characteristics | Baseline (n = 56) |
After 12 Months (n = 56) |
p-Value |
|---|---|---|---|
| Weight (kg) | 144.2 ± 30.3 | 105.6 ± 23.8 | <0.0001 |
| BMI (kg/m2) | 50.5 ± 8.6 | 37.1 ± 8.0 | <0.0001 |
| Body fat (%) | 45.1 ± 7.6 | 35.5 ± 8.2 | <0.0001 |
| FPG (mmol/L) | 6.6 ± 1.7 | 5.6 ± 1.5 | <0.0001 |
| HbA1c (%) | 6.4 ± 1.1 | 5.4 ± 0.8 | <0.0001 |
| Insulin (pmol/L) | 206.1 ± 163.4 | 88.8 ± 102.4 | <0.0001 |
| HOMA-IR | 8.9 ± 7.4 | 3.8 ± 5.3 | <0.0001 |
| Total cholesterol (mmol/L) | 5.3 ± 1.1 | 4.9 ± 0.9 | 0.067 |
| LDL-c (mmol/L) | 3.3 ± 1.0 | 3.1 ± 1.0 | ns |
| HDL (mmol/L) | 1.2 ± 0.3 | 1.4 ± 0.4 | <0.0001 |
| Triglycerides (mmol/L) | 2.0 ± 1.0 | 1.3 ± 0.6 | <0.0001 |
| CRP (nmol/L) | 59.4 ± 65.0 | 32.9 ± 42.8 | 0.024 |
| Interleukin 6 (pg/mL) | 5.5 ± 3.4 | 2.6 ± 2.0 | <0.0001 |
| Interleukin 1 beta (pg/mL) | 9.6 ± 6.7 | 9.1 ± 8.0 | ns |
| Tumor necrosis factor alpha (pg/mL) | 8.3 ± 3.1 | 8.0 ± 3.7 | ns |
| VAT | |||
| CLS (per 100 adipocytes) | 9.0 ± 2.9 | 7.7 ± 3.3 | <0.0001 |
| TNF (AU) | 2.3 ± 1.9 | 1.7 ± 1.9 | ns |
| IL1b (AU) | 1.9 ± 1.2 | 1.2 ± 0.9 | 0.003 |
| TGFb (AU) | 1.5 ± 1.4 | 1.4 ± 1.1 | ns |
| KIT (AU) | 1.1 ± 0.7 | 1.1 ± 0.7 | ns |
| TPSB2 (AU) | 1.0 ± 1.0 | 1.1 ± 1.0 | ns |
| CMA1 (AU) | 1.2 ± 1.1 | 0.8 ± 1.0 | 0.044 |
| SAT | |||
| CLS (per 100 adipocytes) | 4.3 ± 2.1 | 3.6 ± 2.3 | 0.005 |
| TNF (AU) | 1.9 ± 1.8 | 1.5 ± 1.2 | ns |
| IL1b (AU) | 1.9 ± 1.8 | 1.3 ± 0.9 | 0.035 |
| TGFb (AU) | 1.5 ± 0.9 | 1.2 ± 0.7 | 0.024 |
| KIT (AU) | 1.3 ± 0.7 | 1.1 ± 0.8 | ns |
| TPSB2 (AU) | 1.2 ± 0.9 | 1.1 ± 0.7 | ns |
| CMA1 (AU) | 1.3 ± 0.8 | 1.4 ± 1.0 | 0.146 |